arrow
M

Matías Chacón

Ruprecht Karls University Heidelberg
H指数:18
被引数:1,223

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Physician treatment decisions for hormone receptor-positive, HER2-negative early breast cancer in young patients: a Latin American survey

年轻患者激素受体阳性、HER2阴性早期乳腺癌的医师治疗决策:一项拉丁美洲调查

2025-10-150
OA
Sinonasal Sarcomas Management: An International Consensus Statement

鼻腔鼻窦肉瘤的管理:一项国际共识声明

2025-09-010
OAAI
Subcutaneous versus intravenous nivolumab for renal cell carcinoma

皮下注射与静脉注射纳武利尤单抗治疗肾细胞癌

2025-01-010
OAAI
Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients (pts) with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated efficacy and safety results from CheckMate 67T

皮下注射纳武利尤单抗(NIVO SC)与静脉注射纳武利尤单抗(NIVO IV)在既往接受过治疗的晚期或转移性透明细胞肾细胞癌(ccRCC)患者(pts)中的疗效和安全性:CheckMate 67T研究的更新结果

2024-09-010
PRE
Does the recommendation of adjuvant CDK4/6 inhibitors implicate more ovarian suppression in premenopausal patients? A real-world study of a public and a private Argentinean institution
2024-05-020
PRE
Cyclin-dependent kinase inhibitor plus endocrine therapy in HR+/HER2-invasive breast cancer with bone marrow and pancytopenia: a new standard of care? Collaborative multicentric Argentinean real-world study (SUMA-02)
2024-05-020
PRE
SELNET clinical practice guidelines for soft tissue sarcoma and GIST (vol 102, 102312, 2021)
2023-04-010
OAAI
Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report

在EGFR突变的NSCLC患者中使用吉非替尼通过T790M丢失和C797S获得克服对Osimertinib的耐药性: 病例报告

2023-02-016
OA
SELNET clinical practice guidelines for bone sarcoma Critical reviews in oncology/hematology (vol 174, pg 1, 2022)
2022-12-010
PRE
SELNET clinical practice guidelines for bone sarcoma
2022-06-0120
OAAI
SELNET clinical practice guidelines for soft tissue sarcoma and GIST
2022-01-0148
OA
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
2020-11-01103
OAAI